Celularity Inc (CELU): Total Liabilities
$145.39M
As of 2025-12-31
$131.70M
As of 2026-06-30
-10.4%
3-year compound annual growth
-18.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $145.39M | +17.4% | 2026-04-30, Balance as of period end |
| 2024-12-31 | $123.84M | +20.3% | 2026-04-30, Balance as of period end |
| 2023-12-31 | $102.93M | -49.1% | 2025-05-08, Balance as of period end |
| 2022-12-31 | $202.16M | -35.8% | 2024-07-30, Balance as of period end |
| 2021-12-31 | $314.71M | -23.7% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $412.30M | n/m | 2022-03-31, Balance as of period end |
| 2019-12-31 | $28.21M | n/m | 2021-05-24, Balance as of period end |
| 2018-12-31 | $150.6K | n/a | 2020-03-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Celularity Inc (CELU) | 2025-12-31 | $145.39M | +17.4% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $15.78M | +7.4% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $71.25M | -27.0% |
| Alumis Inc. (ALMS) | 2025-12-31 | $110.64M | +36.8% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $306.60M | -7.0% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $189.25M | +45.1% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $85.85M | -19.9% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $11.64M | -0.5% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $62.93M | +21.4% |
Compare CELU, CUE, TRDA, ALMS side by side · Screen every company in Pharmaceutical Preparations ↗